脂肪性肝炎
蛋白激酶A
纤维化
肝纤维化
肝纤维化
医学
AMP活化蛋白激酶
心脏功能不全
激酶
内科学
脂肪肝
生物
安普克
细胞生物学
疾病
心力衰竭
作者
Seojeong Kim,Jae‐Ho Shin,Minjung Seo,Eun Seon Pak,Kyung‐Hwa Jeon,Inhye Moon,Jisoo Kang,Wonhyo Seo,Younghwa Na,Youngjoo Kwon
摘要
Metabolic dysfunction-associated steatohepatitis (MASH) is a significant contributor to hepatocellular carcinoma (HCC). To validate AMPK activation as a therapeutic strategy for MASH-associated liver fibrosis, we investigated the effects of a 4-chloro-benzenesulfonamide derivative named KN21, a novel AMPK activator, on the liver fibrogenic process in a MASH model. In mice fed a choline-deficient, L-amino acid-defined, high fat diet (CDAHFD), KN21 reduced hepatic steatosis, lipid accumulation, and liver fibrosis. In hepatocyte cells treated with palmitic acid and oleic acid (PO), KN21 attenuated lipid accumulation and the release of reactive oxygen species (ROS) and fibrotic mediators. Hepatic stellate cells stimulated with hepatocyte-derived conditioned medium (CM) exhibited increased expression of fibrosis markers, whereas hepatic stellate cells exposed to CM from KN21-treated hepatocytes showed a decrease of fibrosis marker expression. Additionally, KN21 inhibited the activation of human hepatic stellate cells and demonstrated potent antifibrotic activity. These findings underscore the therapeutic potential of pharmacological AMPK activation for the treatment of MASH-associated liver fibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI